Kaleido Biosciences Inc. (KLDO) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. There were no new wire items for KLDO in the last 30 days. The most recent was published May 10, 2022.

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Latest news

25 items

KLDO FAQ

8 questions
  • What does Kaleido Biosciences Inc. do?
    Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is...
  • What is the latest news on KLDO?
    Quantisnow has not tracked any new filings, ratings or press releases for KLDO in the last 30 days. The most recent wire item was published on May 10, 2022.
  • Where does KLDO stock trade?
    Kaleido Biosciences Inc. (KLDO) is listed on NASDAQ.
  • What sector and industry is KLDO in?
    Kaleido Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • When did Kaleido Biosciences Inc. go public?
    Kaleido Biosciences Inc. (KLDO) completed its IPO in 2019.
  • What are analysts saying about KLDO?
    Across the last 4 analyst actions on Kaleido Biosciences Inc., there were 0 upgrades and 1 downgrade. The most recent action was from Chardan Capital: Buy with a $3.00 price target on 2022-01-31.
  • What companies are similar to KLDO?
    Notable peers in the same industry include MRNA (Moderna Inc.), GILD (Gilead Sciences Inc.), BIIB (Biogen Inc.), RVMD (Revolution Medicines Inc.), AMGN (Amgen Inc.). Compare KLDO side-by-side with any of them on Quantisnow.
  • How can I track KLDO on Quantisnow?
    Quantisnow aggregates Kaleido Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KLDO to receive live email and push alerts on every new disclosure.